We lead national and international late phase cancer clinical trials. We test the clinical effectiveness of translational research outputs that come from across our Centre’s strategic areas. These studies test our innovations against current standards of care.
The goal is to deliver effective approaches into clinical practice. We lead trials of new therapies, diagnostics, devices, surgical, and endoscopy approaches. We also conduct the critical monitoring and research studies associated within these trials.
Our key areas of activity include:
- leading molecular risk-stratified pan-European clinical trials in medulloblastoma and their biological studies
- leading genetic risk stratification for the European ‘ALLTogether’ trial in childhood ALL
- CAPP trials of chemo-prevention using aspirin in colorectal cancers
- leading the world’s largest endoscopy trials. They include the clinical development and assessment of innovative devices
- running international multicentre phase III trials of tyrosine kinase inhibitors in chronic myeloid leukaemia
- trials of photodynamic therapies in bladder cancer
- coordinating clinical pharmacology studies within international Phase III trials
- trials-based studies of toxicity and survivorship
Clinical hubs
We deliver a range of open late phase cancer research clinical trials to patients in our region. We work through our clinical hubs at the Great North Children’s Hospital and the Northern Centre for Cancer Care. We work in partnership with NHS Trusts throughout the region and the NIHR North East and North Cumbria LCRN.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
